Latest News

Category: News

See all

Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study

Clinical, News,

Telix is pleased to announce a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective clinical trial investigating the use of O-(2-[18F]fluoroethyl)-L-tyrosine or 18F-FET to image glioblastoma patients with positron emission tomography (PET) (FET-PET). 18F-FET is under development by Telix (referred to as TLX101-CDx) as a complementary diagnostic agent to its TLX101 glioblastoma...

Read more

First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer

Clinical, News,

Telix announces that a first patient has been dosed in the ‘PERTINENCE’ Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder...

Read more

FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®

ASX, News,

Read more

TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021

Events, News,

Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosis) study of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab)...

Read more

Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain

ASX, News,

Telix announces agreement with NUCLIBER S.A. for the distribution of Telix’s prostate cancer investigational imaging product,...

Read more

Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil

ASX, News,

The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging...

Read more

First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea

Events, News,

With our partner, Duchembio, we are pleased to present a first joint symposium on 68Ga-PSMA-PET prostate cancer imaging in...

Read more

NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed

Clinical, News,

Telix is pleased to announce that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art...

Read more

ZIRCON Presentation at International Kidney Cancer Symposium 2021

Events, News,

Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron...

Read more

Australian TGA Approves Illuccix® for Prostate Cancer Imaging

ASX, News,

Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate...

Read more